LitCovid-sample-Enju  

PMC:7228307 / 58034-59627 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T101 0-6 JJ denotes Immune
T102 7-14 NN denotes agonism
T103 15-22 IN denotes through
T104 23-27 NN denotes FcγR
T105 28-39 NN denotes scaffolding
T106 40-49 JJ denotes Agonistic
T107 50-54 NNS denotes mAbs
T108 55-61 VBP denotes induce
T109 62-71 NNS denotes responses
T110 72-74 IN denotes in
T111 75-81 NN denotes target
T112 82-87 NNS denotes cells
T113 88-90 IN denotes by
T114 91-102 VBG denotes stimulating
T115 103-112 NN denotes signaling
T116 113-115 IN denotes of
T117 116-121 PRP-DOLLAR- denotes their
T118 122-131 JJ denotes molecular
T119 132-138 NN denotes target
T120 140-149 RB denotes Typically
T121 149-150 -COMMA- denotes ,
T122 151-155 DT denotes this
T123 156-158 VBZ denotes is
T124 159-161 TO denotes to
T125 162-168 CC denotes either
T126 169-176 VB denotes enhance
T127 177-186 NN denotes antitumor
T128 187-195 NN denotes immunity
T129 196-198 IN denotes by
T130 199-207 VBG denotes engaging
T131 208-221 JJ denotes costimulatory
T132 222-231 NNS denotes molecules
T133 232-234 IN denotes on
T134 235-253 JJ denotes antigen‐presenting
T135 254-259 NNS denotes cells
T136 260-262 CC denotes or
T137 263-264 NN denotes T
T138 265-270 NNS denotes cells
T139 271-272 -LRB- denotes (
T140 272-276 FW denotes i.e.
T141 277-281 NN denotes CD40
T142 281-282 -COMMA- denotes ,
T143 283-288 NN denotes 4‐1BB
T144 288-289 -COMMA- denotes ,
T145 290-294 NN denotes OX40
T146 294-295 -RRB- denotes )
T147 296-298 CC denotes or
T148 299-306 VB denotes promote
T149 307-316 NN denotes apoptosis
T150 317-319 IN denotes by
T151 320-328 VBG denotes engaging
T152 329-334 NN denotes death
T153 335-344 NNS denotes receptors
T154 345-347 IN denotes on
T155 348-354 NN denotes cancer
T156 355-360 NNS denotes cells
T157 361-362 -LRB- denotes (
T158 362-366 FW denotes i.e.
T159 367-370 NN denotes DR4
T160 370-371 -COMMA- denotes ,
T161 372-375 NN denotes DR5
T162 375-376 -COMMA- denotes ,
T163 377-380 NN denotes Fas
T164 380-381 -RRB- denotes )
T165 386-389 DT denotes The
T166 390-394 NN denotes role
T167 395-397 IN denotes of
T168 398-402 NN denotes FcγR
T169 403-405 IN denotes in
T170 406-409 DT denotes the
T171 410-416 NN denotes action
T172 417-419 IN denotes of
T173 420-425 DT denotes these
T174 426-431 NNS denotes types
T175 432-434 IN denotes of
T176 435-439 NNS denotes mAbs
T177 440-447 VBZ denotes appears
T178 448-450 TO denotes to
T179 451-453 VB denotes be
T180 454-463 RB denotes primarily
T181 464-466 IN denotes as
T182 467-468 DT denotes a
T183 469-477 NN denotes scaffold
T184 479-486 NN denotes FcγRIIb
T185 487-489 VBZ denotes is
T186 490-495 RB denotes often
T187 496-499 DT denotes the
T188 500-511 JJ denotes predominate
T189 512-520 NN denotes receptor
T190 521-529 VBN denotes involved
T191 530-533 CC denotes and
T192 534-537 DT denotes the
T193 538-544 NN denotes extent
T194 545-547 IN denotes of
T195 548-551 PRP-DOLLAR- denotes its
T196 552-563 NN denotes involvement
T197 564-566 VBZ denotes is
T198 567-574 JJ denotes complex
T199 576-578 IN denotes In
T200 579-582 DT denotes the
T201 583-587 NN denotes case
T202 588-590 IN denotes of
T203 591-595 NN denotes CD40
T204 595-596 -COMMA- denotes ,
T205 597-600 DT denotes the
T206 601-607 NN denotes degree
T207 608-610 IN denotes of
T208 611-618 NN denotes FcγRIIb
T209 619-630 NN denotes scaffolding
T210 631-638 NN denotes potency
T211 639-641 VBZ denotes is
T212 642-648 VBN denotes linked
T213 649-651 TO denotes to
T214 652-655 DT denotes the
T215 656-663 NN denotes epitope
T216 664-672 NN denotes location
T217 673-675 IN denotes of
T218 676-679 DT denotes the
T219 680-689 VBG denotes targeting
T220 690-693 NN denotes mAb
T221 694-698 IN denotes with
T222 699-706 JJR denotes greater
T223 707-714 NN denotes potency
T224 715-719 VBN denotes seen
T225 720-723 IN denotes for
T226 724-732 NN denotes membrane
T227 733-741 JJ denotes proximal
T228 742-753 NN denotes epitopes.43
T229 753-754 -COMMA- denotes ,
T230 755-758 CD denotes 117
T231 759-761 PRP denotes It
T232 762-764 VBZ denotes is
T233 765-769 RB denotes also
T234 770-780 JJ denotes noteworthy
T235 781-785 IN denotes that
T236 786-795 VBG denotes depending
T237 796-798 IN denotes on
T238 799-802 DT denotes the
T239 803-810 NN denotes epitope
T240 811-819 NN denotes location
T241 819-820 -COMMA- denotes ,
T242 821-824 DT denotes the
T243 825-836 NN denotes scaffolding
T244 837-839 IN denotes of
T245 840-849 NN denotes anti‐CD40
T246 850-854 NNS denotes mAbs
T247 855-858 MD denotes may
T248 859-866 VB denotes convert
T249 867-877 NN denotes antagonist
T250 878-882 NNS denotes mAbs
T251 883-885 TO denotes to
T252 886-895 JJ denotes agonistic
T253 897-908 NN denotes Engineering
T254 909-911 IN denotes of
T255 912-915 DT denotes the
T256 916-920 NN denotes IgG1
T257 921-923 NN denotes Fc
T258 924-930 NN denotes region
T259 931-934 IN denotes for
T260 935-943 VBN denotes enhanced
T261 944-950 CC denotes and/or
T262 951-959 JJ denotes specific
T263 960-967 NN denotes binding
T264 968-970 TO denotes to
T265 971-978 NN denotes FcγRIIb
T266 979-982 MD denotes can
T267 983-990 RB denotes greatly
T268 991-998 VB denotes improve
T269 999-1008 JJ denotes agonistic
T270 1009-1020 NN denotes function.72
T271 1020-1021 -COMMA- denotes ,
T272 1022-1025 CD denotes 118
T273 1025-1026 -COMMA- denotes ,
T274 1027-1030 CD denotes 119
T275 1030-1031 -COMMA- denotes ,
T276 1032-1035 CD denotes 120
T277 1036-1040 JJ denotes Such
T278 1041-1050 NNS denotes mutations
T279 1051-1058 VBD denotes induced
T280 1059-1072 RB denotes significantly
T281 1073-1080 JJR denotes greater
T282 1081-1090 JJ denotes agonistic
T283 1091-1099 NN denotes activity
T284 1100-1102 IN denotes in
T285 1103-1105 DT denotes an
T286 1106-1114 NN denotes anti‐DR5
T287 1115-1120 NN denotes model
T288 1121-1128 IN denotes through
T289 1129-1138 VBN denotes increased
T290 1139-1148 NN denotes induction
T291 1149-1151 IN denotes of
T292 1152-1161 JJ denotes apoptotic
T293 1162-1167 NN denotes death
T294 1168-1171 CC denotes and
T295 1172-1181 VBD denotes decreased
T296 1182-1187 NN denotes tumor
T297 1188-1194 NN denotes growth
T298 1195-1203 VBN denotes compared
T299 1204-1208 IN denotes with
T300 1209-1219 JJ denotes unmodified
T301 1220-1228 NN denotes IgG1.121
T302 1229-1232 DT denotes The
T303 1233-1239 NNP denotes “SELF”
T304 1240-1253 NNS denotes modifications
T305 1254-1258 WDT denotes that
T306 1259-1271 RB denotes dramatically
T307 1272-1275 CC denotes and
T308 1276-1287 RB denotes selectively
T309 1288-1296 VBP denotes increase
T310 1297-1305 NN denotes affinity
T311 1306-1309 IN denotes for
T312 1310-1317 NN denotes FcγRIIb
T313 1318-1322 VBP denotes have
T314 1323-1327 RB denotes also
T315 1328-1332 VBN denotes been
T316 1333-1337 VBN denotes used
T317 1338-1340 TO denotes to
T318 1341-1348 VB denotes enhance
T319 1349-1355 JJ denotes immune
T320 1356-1363 NN denotes agonism
T321 1364-1366 IN denotes in
T322 1367-1369 DT denotes an
T323 1370-1379 NN denotes anti‐OX40
T324 1380-1389 NN denotes model.122
T325 1390-1393 DT denotes The
T326 1394-1410 NN denotes incorporation of
T327 1411-1414 DT denotes the
T328 1415-1416 -DQS- denotes "
T329 1416-1419 NN denotes V12
T330 1419-1420 '' denotes "
T331 1421-1423 NN denotes Fc
T332 1424-1433 NNS denotes mutations
T333 1434-1438 IN denotes into
T334 1439-1443 NN denotes IgG1
T335 1444-1456 RB denotes specifically
T336 1457-1464 VBP denotes enhance
T337 1465-1472 NN denotes FcγRIIb
T338 1473-1484 NN denotes interaction
T339 1485-1493 RB denotes 200‐fold
T340 1493-1494 -COMMA- denotes ,
T341 1495-1505 VBG denotes conferring
T342 1506-1509 DT denotes the
T343 1510-1518 VBN denotes enhanced
T344 1519-1528 JJ denotes agonistic
T345 1529-1537 NN denotes activity
T346 1538-1540 IN denotes of
T347 1541-1543 DT denotes an
T348 1544-1554 NN denotes anti‐CD137
T349 1555-1563 NN denotes antibody
T350 1564-1567 CC denotes and
T351 1568-1570 DT denotes an
T352 1571-1580 NN denotes anti‐OX40
T353 1581-1588 NN denotes mAb.115
T354 1588-1589 -COMMA- denotes ,
T355 1590-1593 CD denotes 122
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","